ABION Inc. is a Korea-based company principally engaged in the research, development and sales of pharmaceuticals. Along with its subsidiaries, the Company operates its business through four segments including product segment, contract research organization (CRO) service segment, research segment and other segment. The Product segment produces and sells diagnostic reagents, research reagents, and stem cell culture medium. The CRO Service segment provides histopathology analysis, molecular genetic analysis, cellular immunoassay, and antibody detection services. The Research segment is engaged in research and development of drugs for protein therapeutics, nucleic acid therapeutics, and antibody therapeutics.

Employees

Sector

Biotechnology & Medical Research

Calendar

10-08 Significant Split/Dividend

More about the company

Quotes

Date	Price	Change	Volume
05/08/26	₩688.00	-4.31%	853,148
04/08/26	₩719.00	+4.51%	751,411
03/08/26	₩688.00	+3.77%	597,014
31/07/26	₩663.00	+7.63%	649,084
30/07/26	₩616.00	-3.14%	469,664

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. Other stock markets 05/08/2026			5-day change	1st Jan Change
688.00 ^KRW	-4.31%		-10.77%	-78.02%

04-07	ABION Announces Preclinical Data Showing IFN-? Antibody Fusion Abn202 Outperforms Trop2-Targeting ADCs	CI
04/04/25	Abion To Divest 5.9 Billion Won Worth Of Shares In Vivozon Inc	RE

Market Cap	61.99B 43.58M 37.75M 35.21M 32.42M 61.06M 4.15B 61.8M 414M 162M 2.07B 164M 160M 6.89B	P/E 2024	-4.02x	P/E 2025	-7.21x
Enterprise Value	33.66B 23.66M 20.5M 19.12M 17.6M 33.15M 2.25B 33.55M 225M 88.04M 1.13B 88.89M 86.93M 3.74B	EV / Sales 2024	282x	EV / Sales 2025	288x
Free-Float	67.24%	Yield 2024 *	-	Yield 2025	-

04-07	ABION Announces Preclinical Data Showing IFN-? Antibody Fusion Abn202 Outperforms Trop2-Targeting ADCs	CI
04/04/25	Abion To Divest 5.9 Billion Won Worth Of Shares In Vivozon Inc	RE
29/12/24	Nuon Co., Ltd. completed the acquisition of 4.06% stake in ABION Inc. from KPM TECH Co., Ltd..	CI
25/12/24	KPM TECH Co., Ltd. announced that it has received KRW 5.999999711 billion in funding from ABION Inc.	CI
22/12/24	Nuon Co., Ltd. agreed to acquire 4.06% stake in ABION Inc. from KPM TECH Co., Ltd. for KRW 8 billion.	CI
22/12/24	ABION Inc. announced that it has received KRW 8.0011152 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
17/12/24	KPM TECH Co., Ltd. announced that it expects to receive KRW 5.999999711 billion in funding from ABION Inc.	CI
04/12/24	ABION Inc. completed the acquisition of 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc..	CI
04/12/24	ABION Inc. announced that it has received KRW 20.019993378 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
10/11/24	ABION Inc. announced that it expects to receive KRW 20.019993378 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
10/11/24	ABION Inc. agreed to acquire 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc. for KRW 20.1 billion.	CI
27/10/24	ABION Inc. announced that it expects to receive KRW 9.999995616 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
27/12/23	Abion Inc. announced that it has received KRW 7.999997049 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Gencurix Inc.	CI

1 day	-4.31%
1 week	-10.77%
Current month	+3.77%
1 month	-3.23%
3 months	-73.69%
6 months	-81.65%
Current year	-78.02%

Abion Inc. Share Price

Stocks

A203400

KR7203400007

Biotechnology & Medical Research

Valuation: Abion Inc.

Chart: Abion Inc.

Latest news : Abion Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Abion Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Manager	Title	Age	Since
Young-Gi Shin CEO	Chief Executive Officer	55	31/07/2010
Seong-Yun Woo DFI	Director of Finance/CFO	45	27/03/2025
Gi-Ryong Jang COO	Chief Operating Officer	46	31/12/2025

Director	Title	Age	Since
Young-Gi Shin BRD	Director/Board Member	55	30/12/2014
Jin-Wook Yang BRD	Director/Board Member	56	24/03/2022
Geun-Chul Park BRD	Director/Board Member	70	-

Date	Insider	Type	Quantity	% Market Cap.
08/12/25	Sun-mi Chang	Free	27	0.0001%
08/12/25	Yang-mi Lim	Buy	115	0.0002%
08/12/25	Yang-mi Lim	Free	92	0.0002%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABION INC.	-4.31%	-10.77%	-81.63%	-84.48%	45.4M
WUXI APPTEC CO., LTD.	+4.35%	+19.90%	+60.59%	+95.21%	62.53B
ARGENX SE	+2.83%	-3.03%	+27.40%	+67.25%	52.43B
BIONTECH SE	+0.91%	-0.29%	-16.22%	-13.43%	23.1B
INSMED INCORPORATED	+0.27%	-4.91%	-10.99%	+350.30%	21.4B
WUXI BIOLOGICS (CAYMAN) INC.	+0.40%	+5.29%	+30.11%	-9.63%	21.17B
GENMAB A/S	+0.75%	-0.84%	+33.80%	-25.25%	17.76B
PHARMAESSENTIA CORPORATION	+9.88%	+19.73%	+229.67%	+385.49%	15.47B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+2.08%	-3.28%	+21.67%	+564.59%	14.68B
EXELIXIS, INC.	+1.25%	+0.34%	+54.03%	+179.72%	14.08B
Average	+1.84%	+4.46%	+34.84%	+150.98%	24.27B
Weighted average by Cap.	+2.76%	+4.59%	+43.19%	+135.13%

	2024	2025
Net sales	760M 534K 463K 432K 397K 748K 50.82M 757K 5.07M 1.99M 25.41M 2.01M 1.96M 84.47M	880M 619K 536K 500K 460K 867K 58.88M 877K 5.87M 2.3M 29.44M 2.32M 2.27M 97.86M
Net income	-43.38B -30.5M -26.42M -24.64M -22.69M -42.73M -2.9B -43.25M -290M -113M -1.45B -115M -112M -4.82B	-29.06B -20.43M -17.7M -16.51M -15.2M -28.63M -1.94B -28.98M -194M -76.03M -972M -76.76M -75.07M -3.23B
Net Debt	14.05B 9.87M 8.55M 7.98M 7.35M 13.84M 940M 14M 93.75M 36.75M 470M 37.1M 36.28M 1.56B	-28.33B -19.92M -17.26M -16.09M -14.82M -27.91M -1.9B -28.25M -189M -74.12M -948M -74.83M -73.19M -3.15B

1 week	610	757
1 month	574	900
Current year	570	4,335
1 year	570	4,510
3 years	570	7,277.78
5 years	570	14,694.44
10 years	570	14,694.44